mal-phe-c-4-vc-pab-dmea-pnu-159682

Ethyl 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate has an inhibitory effect on coagulation factor Xa, and it can be used in the study of thrombophlebitis, atherosclerosis, cerebral embolism, stroke and pulmonary embolism.

Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)-, (3aR,4S,9bS)-rel- is an estrogen receptor beta (ERβ) agonist.

Compound Fr13857 is a useful organic compound for research related to life sciences. The catalog number is Fr13857 and the CAS number is 31270-80-1.

1H-Pyrrolo[2,1-c][1,2,4]benzothiadiazine, 2,3,3a,4-tetrahydro-, 5,5-dioxide, (3aR)- is a low activity isomer of S 18986. S 18986 is a AMPA receptor positive modulator with EC2 (Concentration that doubles the intensity of the AMPA-induced current) of 35 μM.

MC-VC-PAB-NH2 TFA is a cleavable linker for antibody-drug conjugates (ADCs) [1] utilized in their synthesis.

Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan is a linker molecule employed in the synthesis of antibody-drug conjugates (ADCs), demonstrating potent antitumor activity both in vitro and in vivo [1].

Gly-Mal-Gly-Gly-Phe-Gly-amide-methylcyclopropane-Exatecan is a compound utilized in the synthesis of Antibody-Drug Conjugates (ADCs) [1].

PNU-159682 carboxylic acid is a potent ADCs cytotoxin,PNU-159682 carboxylic acid has protein fold and diverse functions.

MC-VC-PAB-NH2 is a cleavable linker vital in ADC synthesis. MC-VC-PAB-NH2 joins cytotoxic drugs to antibodies, enabling precise delivery to cells or proteins. The cleavable nature ensures controlled drug release, optimizing ADC effectiveness.

Fmoc-Phe-Lys(Trt)-PAB is a cleavable linker for antibody-drug conjugates (ADCs) synthesis.

Mc-Gly-Gly-Phe-Gly-PAB-OH, also known as Mc-GGFG-PAB-OH, serves as a cleavable ADC linker exclusively employed in the synthesis of antibody-drug conjugates (ADCs).

Mal-PEG2-Val-Cit-amido-PAB-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

4'-O-Methyllucenin II (Diosmetin 6,8-di-C-glucoside) is a useful organic compound for research related to life sciences and the catalog number is T123819.

Fmoc-Phe-Lys(Trt)-PAB-PNP is a cleavable linker for antibody-drug conjugate (ADC) synthesis, specifically designed for use in ADC synthesis.

MAL-di-EG-Val-Cit-PAB-MMAF refers to a chemical compound that comprises the linker (MAL-di-EG-Val-Cit-PAB) and the potent blocker of tubulin polymerization (MMAF, Monomethyl auristatin F)[1].

Mal-VC-PAB-PNP-CDN-A is a conjugate comprised of an agent and a linker, utilized in antibody-drug conjugates (ADC) [1] [2].

Compound 15, Mal-PEG8-Phe-Lys-PAB-Exatecan, is an antibody-drug conjugate (ADC) comprised of the degradable linker Mal-PEG8-Phe-Lys-PAB and the cytotoxic agent Exatecan [1].

MC-vc-PAB-Tubulysin M is a conjugate composed of a cleavable ADC linker (MC-vc-PAB) and the cytotoxic tubulin inhibitor Tubulysin M, which inhibits tubulin polymerization, resulting in cell cycle arrest and apoptosis.

7-Methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-amine is a building block.1It has been used in the synthesis of PI3K inhibitors. 1.Scott, W.J., Hentemann, M.F., Rowley, R.B., et al.Discovery and SAR of novel 2,3-dihydroimidazo[1,2-c]quinazoline PI3K inhibitors: Identification of copanlisib (BAY 80-6946)ChemMedChem.11(14)1517-1530(2016)

Mal-VC-PAB-DM1, a drug-linker conjugate for antibody-drug conjugates (ADCs), exhibits potent antitumor activity. It incorporates DM1, a potent microtubule-disrupting agent, connected through the ADC linker Mal-VC-PAB [1].

Mal-Phe-C4-VC-PAB-MMAE is a chemical compound resulting from the conjugation of monomethyl auristatin E (MMAE), a potent tubulin inhibitor serving as a toxin payload in antibody-drug conjugates, with a Mal-Phe-C4-VC-PAB linker.

Mal-PEG8-Val-Cit-PAB-MMAE is a cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) TFA is a cleavable linker utilized in the synthesis of antibody-drug conjugates (ADCs).

Compound D7, also known as Mal-PEG8-Val-Ala-PAB-SB-743921, is a drug-linker conjugate for antibody-drug conjugates (ADC). It comprises the KSP inhibitor SB-743921 connected through a linker and is utilized in the synthesis of ADCs [1].

Fmoc-Gly3-VC-PAB-MMAE is a drug-linker conjugate utilized in antibody-drug conjugates (ADCs), composed of the potent cytotoxic agent Monomethyl auristatin E (MMAE) tethered via a cleavable linker [1].

Fmoc-Phe(4-CN)-OH is an N-Fmoc protected phenylalanine derivative and potentially useful synthetic intermediate

Mal-PEG4-VC-PAB-DMEA is a cleavable ADC linker that incorporates a Maleimide moiety. It is employed in the synthesis of antibody-drug conjugates (ADCs)[1].

Phe-Lys(Trt)-PAB is a cathepsin-cleavable linker utilized in the development of antibody-drug conjugates (ADCs)[1], serving as a crucial component for facilitating the release of therapeutic agents within targeted cells.

Mal-amido-PEG2-Val-Cit-PAB-PNP is a cleavable 2-unit polyethylene glycol (PEG) based ADC linker utilized in the construction of antibody-drug conjugates (ADCs)[1].

Gly3-VC-PAB-MMAE is a chemical compound comprised of a cleavable antibody-drug conjugate (ADC) linker, Gly3-VC-PAB, and a potent inhibitor of tubulin, MMAE. It is utilized in the synthesis of ADCs.

DBCO-(PEG2-VC-PAB-MMAE)2 consists of Monomethyl auristatin E (MMAE), a toxin payload in antibody-drug conjugate [1], conjugated to the cleavable linker DBCO-(PEG2-VC-PAB)2. MMAE, a potent tubulin inhibitor, serves as the cytotoxic component in this formulation.

MAL-di-EG-Val-Cit-PAB-MMAE comprises the linker MAL-di-EG-Val-Cit-PAB and the potent tubulin inhibitor MMAE, which are essential components of antibody-drug conjugates (ADCs).

DBCO-PEG4-VC-PAB-MMAE, an ADC linker comprising DBCO-PEG4-VC-PAB coupled with the tubulin polymerization inhibitor MMAE, serves as a key component in the formulation of antibody-drug conjugates (ADCs). MMAE, a synthetic derivative of dolastatin 10, inhibits tubulin polymerization, acting as a potent mitotic inhibitor.

N3-PEG3-VC-PAB-MMAF (Comp T-88-5) is a drug-linker conjugate for antibody-drug conjugates (ADCs) that comprises the ADC linker N3-PEG3-VC-PAB and the microtubule-disrupting agent MMAF [1]. This click chemistry reagent boasts an Azide group enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAC) with Alkyne-bearing molecules. Additionally, it can engage in strain-promoted alkyne-azide cycloaddition (SPAAC) with compounds presenting DBCO or BCN groups.

Mal-amido-PEG8-Val-Ala-PAB-SG3200 is an antibody-drug conjugate (ADC) linker[1].

Amidate-VC-PAB-MMAF, a cleavable ADC linker (Amidate-VC-PAB) combined with a potent tubulin polymerization inhibitor (MMAF), is utilized in the synthesis of antibody-drug conjugates (ADCs) to decrease off-target cytotoxicity[1].

DBCO-(PEG)3-VC-PAB-MMAE is a chemical compound where monomethyl auristatin E (MMAE), a potent tubulin inhibitor acting as a toxin payload in antibody-drug conjugates, is conjugated to a DBCO-(PEG)3-vc-PAB linker.

7-N-(4-Hydroxyphenyl)mitomycin C is a bioactive chemical.

3-(9-Chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)benzeneacetamide inhibits multidrug resistance protein (MRP1).

Mal-Phe-C4-VC-PAB-DMEA-PNU-159682 is a drug-linker conjugate utilized in antibody-drug conjugate (ADC) therapy. It comprises the ADC linker Mal-Phe-C4-VC-PAB and the potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 encompasses metabolites of nemorubicin (MMDX) derived from liver microsomes, as well as the ADC cytotoxin PNU-159682[1].

4-Chloro-2-(2,6-dioxopiperidin-3-yl)-1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione is a useful organic compound for research related to life sciences and the catalog number is T64660.

PNU-159682, a metabolite of anthracycline neomycin, is a DNA topoisomerase II inhibitor with excellent cytotoxicity.

Fmoc-Phe(4-NH2)-OH is an amino acid derivative and has a wide range of applications in life science related research.

Azide-PEG4-VC-PAB-Doxorubicin is an agent-linker conjugate for antibody-drug conjugate (ADC) applications, consisting of the cytotoxic anthracycline antibiotic Doxorubicin attached via the Azide-PEG4-VC-PAB linker [1].

Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan is a conjugated compound utilized in the synthesis of antibody-drug conjugates (ADCs). This chemical includes a topoisomerase inhibitor derivative attached via a linker, facilitating the connection to a specific ligand unit[1].

Mal-PEG8-Val-Cit-PAB-MMAF is a drug-linker conjugate utilized for antibody-drug conjugates (ADCs), comprising a cleavable linker system and the potent tubulin inhibitor monomethyl auristatin F (MMAF), aimed at targeted cancer therapy.

5'-O-Benzoyl-2'-O,4'-C-methyleneuridine is a Nucleoside Derivative - LNA related nucleoside; Protected nucleoside with NH2/OH open.

Mal-PEG4-Val-Cit-PAB, a cleavable ADC linker incorporating a Maleimide moiety, finds application in the construction of antibody-drug conjugates (ADCs)[1].

PC5-VC-PAB-MMAE is a conjugate comprising the ADC linker (PC5-VC-PAB) and the potent tubulin inhibitor (MMAE), functioning as an agent-linker conjugate for antibody-drug conjugates (ADC) [1].